Új-Zéland - angol - Medsafe (Medicines Safety Authority)

pharmacia limited company trading as pharmacia - vincristine sulfate 1 mg/ml - solution for injection - 1 mg/ml - active: vincristine sulfate 1 mg/ml excipient: mannitol water for injection

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - vincristine sulfate 2mg - solution for injection - 2 mg - active: vincristine sulfate 2mg excipient: lactose monohydrate water for injection sodium chloride water for injection

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - vincristine sulfate 5mg - solution for injection - 5 mg - active: vincristine sulfate 5mg excipient: lactose monohydrate water for injection sodium chloride water for injection

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - vincristine sulfate 1 mg/ml;  ;   - solution for injection - 1 mg/ml - active: vincristine sulfate 1 mg/ml     excipient: mannitol sodium hydroxide sulfuric acid water for injection

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; water for injections; sodium hydroxide; sulfuric acid - vincristine is used primarily in the treatment of acute leukaemia, usually as a component of various chemotherapeutic regimens. it has also been used as part of combination therapy in the treatment of hodgkin's disease, non-hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung and gynaecological tumours of childhood. vincristine may be useful in patients with true idiopathic thrombocytopenic purpura resistant to the usual treatment, but not recommended as primary treatment for this disorder

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sodium hydroxide; sulfuric acid; water for injections - chile vincristine sulfate is indicated alone or in combination with other antitumor therapies for the treatment of: ? leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia and blastic crisis of chronic mylogenous leukaemia. ? malignant lymphomas, including hodgkin?s disease and non-hodgkin?s lymphomas ? lung cancer (small cell bronchogenic carcinoma) ? wilms? tumor ? neuroblastoma ? ewing?s sarcomas ? true idiopathic thrombocytopenic purpura ? rhabdomyosarcoma ? osteogenic sarcoma ? mycosis fungoides ? uterine cervix cancer ? malignant melanoma ? breast carcinoma croatia vincristine is used primarily in the treatment of acute leukaemia, usually as a component of various chemotherapeutic regimens. it has also been used as part of combination therapy in the treatment of hodgkin's disease, non-hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung and gynaecological tumours of childhood. vincristine may be useful in patients with true idiopathic thrombocytopenic purpura resistant to the usual treatment but is not recommended as primary treatment for this disorder.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sulfuric acid; water for injections; sodium hydroxide - in combination with other chemotherapeutic agents, vincristine is indicated for the treatment of acute leukaemia and malignant lymphomas, including hodgkin?s disease, lymphosarcoma and reticulosarcoma.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sulfuric acid; water for injections; sodium hydroxide - in combination with other chemotherapeutic agents, vincristine is indicated for the treatment of acute leukaemia and malignant lymphomas, including hodgkin?s disease, lymphosarcoma and reticulosarcoma.

Szingapúr - angol - HSA (Health Sciences Authority)

pfizer private limited - vincristine sulphate - injection - 1 mg/ml - vincristine sulphate 1 mg/ml

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - vincristine sulfate - solution for injection - 1mg/1ml